ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years
Liang Liu
Matched on ORCID iD 0009-0002-0403-6580; OpenAlex author ID A5147157934. Sources: ClinicalTrials.gov.
Their work
- Papers
- 3 (first author 0, last author 2)
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 1
- Collaborators
- 19
2021: 1 paper · 2022: none · 2023: none · 2024: 1 trial · 2025: none · 2026: 2 papers
Papers 3
- DDR1 sustains ferroptosis resistance in pancreatic ductal adenocarcinoma via SLC40A1-mediated iron homeostasis. Last author DOI 10.1038/s41388-026-03980-w↗
- RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Non-canonical Hedgehog Signaling. Last author DOI 10.1158/0008-5472.can-26-0333↗
- Comments on "Importance of Normalization of CA19-9 Levels After Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer". Co-author DOI 10.1097/sla.0000000000004538↗
Trials 1
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Taochen He · 2 shared papers, 2026 · strength 0.46
- Wenhui Lou · 2 shared papers, 2026 · strength 0.46
- Chao Song · 1 shared paper, 2026 · strength 0.23
- Ning Pu · 1 shared paper, 2026 · strength 0.23
- Chaoyu Pang · 1 shared paper, 2026 · strength 0.23
- Hanlin Yin · 1 shared paper, 2026 · strength 0.23
- Haibo Wang · 1 shared paper, 2026 · strength 0.23
- Wenquan Wang · 1 shared paper, 2026 · strength 0.23
- Yifei Zhang · 1 shared paper, 2026 · strength 0.23
- Qiangda Chen · 1 shared paper, 2026 · strength 0.23
- Yazhou Wang · 1 shared paper, 2026 · strength 0.23
- Yanfei An · 1 shared paper, 2026 · strength 0.23
- Jing‐Jing Li · 1 shared paper, 2026 · strength 0.23
- Luting Zhang · 1 shared paper, 2026 · strength 0.23
- Yun Jin · 1 shared paper, 2026 · strength 0.23
- Wenchuan Wu · 1 shared paper, 2026 · strength 0.23
- Shuo Li · 1 shared paper, 2021 · strength 0.17
- Huaxiang Xu · 1 shared paper, 2021 · strength 0.17
- Xianjun Yu · 1 shared paper, 2021 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.